JP2009528389A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009528389A5 JP2009528389A5 JP2008557512A JP2008557512A JP2009528389A5 JP 2009528389 A5 JP2009528389 A5 JP 2009528389A5 JP 2008557512 A JP2008557512 A JP 2008557512A JP 2008557512 A JP2008557512 A JP 2008557512A JP 2009528389 A5 JP2009528389 A5 JP 2009528389A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydrothiopheno
- pyrimidine
- dione
- methyl
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 229910052757 nitrogen Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 5
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 5
- 239000011593 sulfur Chemical group 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- -1 1,3-oxazolin-2-yl Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- AYIMIOWWJQTGRR-UHFFFAOYSA-N 1,5-dimethyl-3-(2-methylpropyl)-6-(1,3-oxazol-2-yl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC(C)C)C(=O)N(C)C=2SC=1C1=NC=CO1 AYIMIOWWJQTGRR-UHFFFAOYSA-N 0.000 claims 1
- XSACIUDXRIJHPP-UHFFFAOYSA-N 1,5-dimethyl-3-prop-2-ynylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound CN1C(=O)N(CC#C)C(=O)C2=C1SC=C2C XSACIUDXRIJHPP-UHFFFAOYSA-N 0.000 claims 1
- QANGOZVMTSSFBT-VIFPVBQESA-N 1,5-dimethyl-6-[(4s)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]-3-(2-methylpropyl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC(C)C)C(=O)N(C)C=2SC=1C1=N[C@@H](C)CO1 QANGOZVMTSSFBT-VIFPVBQESA-N 0.000 claims 1
- RJRSFBWAWVWPSE-SECBINFHSA-N 1,5-dimethyl-6-[(5r)-5-methyl-4,5-dihydro-1,3-oxazol-2-yl]-3-(2-methylpropyl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC(C)C)C(=O)N(C)C=2SC=1C1=NC[C@@H](C)O1 RJRSFBWAWVWPSE-SECBINFHSA-N 0.000 claims 1
- GYKMASORTIXMGF-UHFFFAOYSA-N 1-ethyl-6-(furan-2-yl)-5-methyl-3-(2-methylpropyl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC(C)C)C(=O)N(CC)C=2SC=1C1=CC=CO1 GYKMASORTIXMGF-UHFFFAOYSA-N 0.000 claims 1
- RDMCECHQIVHPLV-UHFFFAOYSA-N 3,5-dimethyl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound N1C(=O)N(C)C(=O)C2=C1SC=C2C RDMCECHQIVHPLV-UHFFFAOYSA-N 0.000 claims 1
- FXAQLDZSORIKFL-UHFFFAOYSA-N 3,5-dimethyl-6-thiophen-2-yl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound S1C=2NC(=O)N(C)C(=O)C=2C(C)=C1C1=CC=CS1 FXAQLDZSORIKFL-UHFFFAOYSA-N 0.000 claims 1
- DQOIGKIGTHFRPK-UHFFFAOYSA-N 3-(cyclopropylmethyl)-5-methyl-6-thiophen-2-yl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound O=C1C=2C(C)=C(C=3SC=CC=3)SC=2NC(=O)N1CC1CC1 DQOIGKIGTHFRPK-UHFFFAOYSA-N 0.000 claims 1
- FLVZBFGCVGNIJI-UHFFFAOYSA-N 3-(cyclopropylmethyl)-6-(furan-2-yl)-5-methyl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound O=C1C=2C(C)=C(C=3OC=CC=3)SC=2NC(=O)N1CC1CC1 FLVZBFGCVGNIJI-UHFFFAOYSA-N 0.000 claims 1
- BGXYXSGIGDBGLB-UHFFFAOYSA-N 3-ethyl-1,5-dimethyl-6-(1,3-thiazol-2-yl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)N(C)C=2SC=1C1=NC=CS1 BGXYXSGIGDBGLB-UHFFFAOYSA-N 0.000 claims 1
- SYHSYRHGGSPNBV-UHFFFAOYSA-N 3-ethyl-1,5-dimethyl-6-(1h-pyrrol-2-yl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)N(C)C=2SC=1C1=CC=CN1 SYHSYRHGGSPNBV-UHFFFAOYSA-N 0.000 claims 1
- MWHXFQLBIPLRHU-UHFFFAOYSA-N 3-ethyl-1,5-dimethyl-6-(4-methylthiophen-2-yl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)N(C)C=2SC=1C1=CC(C)=CS1 MWHXFQLBIPLRHU-UHFFFAOYSA-N 0.000 claims 1
- LBYZFZDBAAUYAN-UHFFFAOYSA-N 3-ethyl-1,5-dimethyl-6-pyridin-2-ylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)N(C)C=2SC=1C1=CC=CC=N1 LBYZFZDBAAUYAN-UHFFFAOYSA-N 0.000 claims 1
- SYPYECJBYHRXAH-UHFFFAOYSA-N 3-ethyl-5,6-dimethyl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound O=C1N(CC)C(=O)NC2=C1C(C)=C(C)S2 SYPYECJBYHRXAH-UHFFFAOYSA-N 0.000 claims 1
- CNIUKLMBKSPBTK-UHFFFAOYSA-N 3-ethyl-5-(furan-2-yl)-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound C1=2C(=O)N(CC)C(=O)NC=2SC=C1C1=CC=CO1 CNIUKLMBKSPBTK-UHFFFAOYSA-N 0.000 claims 1
- HKDPFHNYMVTSDK-UHFFFAOYSA-N 3-ethyl-5-methyl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound O=C1N(CC)C(=O)NC2=C1C(C)=CS2 HKDPFHNYMVTSDK-UHFFFAOYSA-N 0.000 claims 1
- XFMIKIFGGADBEX-UHFFFAOYSA-N 3-ethyl-5-methyl-6-(1,3-oxazol-2-yl)-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)NC=2SC=1C1=NC=CO1 XFMIKIFGGADBEX-UHFFFAOYSA-N 0.000 claims 1
- FGSSLGCUVFSUQF-UHFFFAOYSA-N 3-ethyl-5-methyl-6-(1,3-thiazol-2-yl)-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)NC=2SC=1C1=NC=CS1 FGSSLGCUVFSUQF-UHFFFAOYSA-N 0.000 claims 1
- VWPYAFLMACTLRC-UHFFFAOYSA-N 3-ethyl-5-methyl-6-(1h-pyrrol-2-yl)-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)NC=2SC=1C1=CC=CN1 VWPYAFLMACTLRC-UHFFFAOYSA-N 0.000 claims 1
- ZAHFSDJSKSJCLX-UHFFFAOYSA-N 3-ethyl-5-methyl-6-(3-methylthiophen-2-yl)-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)NC=2SC=1C=1SC=CC=1C ZAHFSDJSKSJCLX-UHFFFAOYSA-N 0.000 claims 1
- ANNNZGGUHBHDRB-UHFFFAOYSA-N 3-ethyl-5-methyl-6-(4-methylthiophen-2-yl)-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)NC=2SC=1C1=CC(C)=CS1 ANNNZGGUHBHDRB-UHFFFAOYSA-N 0.000 claims 1
- JEVQRXBELYXZCN-UHFFFAOYSA-N 3-ethyl-5-methyl-6-pyridin-2-yl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)NC=2SC=1C1=CC=CC=N1 JEVQRXBELYXZCN-UHFFFAOYSA-N 0.000 claims 1
- BQRWKTYJZMSGRG-UHFFFAOYSA-N 3-ethyl-5-methyl-6-thiophen-2-yl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)NC=2SC=1C1=CC=CS1 BQRWKTYJZMSGRG-UHFFFAOYSA-N 0.000 claims 1
- USWYIELLUJCANN-UHFFFAOYSA-N 3-ethyl-5-methyl-6-thiophen-3-yl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)NC=2SC=1C=1C=CSC=1 USWYIELLUJCANN-UHFFFAOYSA-N 0.000 claims 1
- QIHGXPWTOIPJBU-UHFFFAOYSA-N 3-ethyl-6-(2-methoxypyridin-3-yl)-5-methyl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)NC=2SC=1C1=CC=CN=C1OC QIHGXPWTOIPJBU-UHFFFAOYSA-N 0.000 claims 1
- YGGIDNUCBXJIFW-UHFFFAOYSA-N 3-ethyl-6-(6-methoxypyridin-3-yl)-5-methyl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)NC=2SC=1C1=CC=C(OC)N=C1 YGGIDNUCBXJIFW-UHFFFAOYSA-N 0.000 claims 1
- KOVVTTPRNSFLJW-UHFFFAOYSA-N 3-ethyl-6-(furan-2-yl)-1,5-dimethylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)N(C)C=2SC=1C1=CC=CO1 KOVVTTPRNSFLJW-UHFFFAOYSA-N 0.000 claims 1
- VBOJNVFLQMBIKM-UHFFFAOYSA-N 3-ethyl-6-(furan-2-yl)-5-methyl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)NC=2SC=1C1=CC=CO1 VBOJNVFLQMBIKM-UHFFFAOYSA-N 0.000 claims 1
- IFHHDEMGUPBEJJ-UHFFFAOYSA-N 3-ethyl-6-(furan-3-yl)-1,5-dimethylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)N(C)C=2SC=1C=1C=COC=1 IFHHDEMGUPBEJJ-UHFFFAOYSA-N 0.000 claims 1
- FIHCUITWGOZCGQ-UHFFFAOYSA-N 3-ethyl-6-(furan-3-yl)-5-methyl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)NC=2SC=1C=1C=COC=1 FIHCUITWGOZCGQ-UHFFFAOYSA-N 0.000 claims 1
- SIVMRDWPCWHXHT-UHFFFAOYSA-N 3-ethyl-n,5-dimethyl-2,4-dioxo-1h-thieno[2,3-d]pyrimidine-6-carboxamide Chemical compound O=C1N(CC)C(=O)NC2=C1C(C)=C(C(=O)NC)S2 SIVMRDWPCWHXHT-UHFFFAOYSA-N 0.000 claims 1
- PCMWKHAVVPWRIN-UHFFFAOYSA-N 5-methyl-2,4-dioxo-3-propyl-1h-thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound O=C1N(CCC)C(=O)NC2=C1C(C)=C(C(O)=O)S2 PCMWKHAVVPWRIN-UHFFFAOYSA-N 0.000 claims 1
- BXBGZNKUNTXGEO-UHFFFAOYSA-N 5-methyl-3-(2-methylpropyl)-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C(=O)NC2=C1C(C)=CS2 BXBGZNKUNTXGEO-UHFFFAOYSA-N 0.000 claims 1
- PHDWDSRETAHXQX-UHFFFAOYSA-N 5-methyl-3-(2-methylpropyl)-6-(1,3-oxazol-2-yl)-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC(C)C)C(=O)NC=2SC=1C1=NC=CO1 PHDWDSRETAHXQX-UHFFFAOYSA-N 0.000 claims 1
- BBTQJFJLGVRVGB-UHFFFAOYSA-N 5-methyl-3-(2-methylpropyl)-6-(1,3-oxazol-4-yl)-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC(C)C)C(=O)NC=2SC=1C1=COC=N1 BBTQJFJLGVRVGB-UHFFFAOYSA-N 0.000 claims 1
- CODHAALJGOWLRM-UHFFFAOYSA-N 5-methyl-3-prop-2-enyl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound N1C(=O)N(CC=C)C(=O)C2=C1SC=C2C CODHAALJGOWLRM-UHFFFAOYSA-N 0.000 claims 1
- CAKRFHARQNNGOH-UHFFFAOYSA-N 5-methyl-3-prop-2-ynyl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound N1C(=O)N(CC#C)C(=O)C2=C1SC=C2C CAKRFHARQNNGOH-UHFFFAOYSA-N 0.000 claims 1
- PHRDOZYOYVDPFF-SSDOTTSWSA-N 5-methyl-6-[(4r)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]-3-propyl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CCC)C(=O)NC=2SC=1C1=N[C@H](C)CO1 PHRDOZYOYVDPFF-SSDOTTSWSA-N 0.000 claims 1
- HVKXGKCYOSLVRE-QMMMGPOBSA-N 5-methyl-6-[(4s)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]-3-(2-methylpropyl)-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC(C)C)C(=O)NC=2SC=1C1=N[C@@H](C)CO1 HVKXGKCYOSLVRE-QMMMGPOBSA-N 0.000 claims 1
- PHRDOZYOYVDPFF-ZETCQYMHSA-N 5-methyl-6-[(4s)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]-3-propyl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CCC)C(=O)NC=2SC=1C1=N[C@@H](C)CO1 PHRDOZYOYVDPFF-ZETCQYMHSA-N 0.000 claims 1
- MPZOAJOWUXAAHQ-MRVPVSSYSA-N 5-methyl-6-[(5r)-5-methyl-4,5-dihydro-1,3-oxazol-2-yl]-3-(2-methylpropyl)-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC(C)C)C(=O)NC=2SC=1C1=NC[C@@H](C)O1 MPZOAJOWUXAAHQ-MRVPVSSYSA-N 0.000 claims 1
- LDYRNWBGKMWMKV-UHFFFAOYSA-N 6-(1-benzylpyrazol-4-yl)-3-ethyl-5-methyl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)NC=2SC=1C(=C1)C=NN1CC1=CC=CC=C1 LDYRNWBGKMWMKV-UHFFFAOYSA-N 0.000 claims 1
- QDCJXMUGQRYYGC-UHFFFAOYSA-N 6-(3-benzyl-1,2,4-oxadiazol-5-yl)-3-ethyl-5-methyl-1H-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)NC=2SC=1C(ON=1)=NC=1CC1=CC=CC=C1 QDCJXMUGQRYYGC-UHFFFAOYSA-N 0.000 claims 1
- GVSFJJXEFOKQEW-UHFFFAOYSA-N 6-(4,5-dihydro-1,3-oxazol-2-yl)-3-ethyl-5-methyl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC)C(=O)NC=2SC=1C1=NCCO1 GVSFJJXEFOKQEW-UHFFFAOYSA-N 0.000 claims 1
- PHYRLJHGBFFWBA-UHFFFAOYSA-N 6-(furan-2-yl)-3,5-dimethyl-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound S1C=2NC(=O)N(C)C(=O)C=2C(C)=C1C1=CC=CO1 PHYRLJHGBFFWBA-UHFFFAOYSA-N 0.000 claims 1
- AWAIRQYZSUKKFE-UHFFFAOYSA-N 6-(furan-2-yl)-5-methyl-3-(2-methylpropyl)-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC(C)C)C(=O)NC=2SC=1C1=CC=CO1 AWAIRQYZSUKKFE-UHFFFAOYSA-N 0.000 claims 1
- APOXOOAUNRTWIW-UHFFFAOYSA-N 6-(furan-3-yl)-5-methyl-3-(2-methylpropyl)-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC=1C=2C(=O)N(CC(C)C)C(=O)NC=2SC=1C=1C=COC=1 APOXOOAUNRTWIW-UHFFFAOYSA-N 0.000 claims 1
- FMGXGQAJAYPVAB-NSHDSACASA-N 6-[(4s)-4-ethyl-4,5-dihydro-1,3-oxazol-2-yl]-1,5-dimethyl-3-(2-methylpropyl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC[C@H]1COC(C2=C(C=3C(=O)N(CC(C)C)C(=O)N(C)C=3S2)C)=N1 FMGXGQAJAYPVAB-NSHDSACASA-N 0.000 claims 1
- JQJTULYLWIREKP-JTQLQIEISA-N 6-[(4s)-4-ethyl-4,5-dihydro-1,3-oxazol-2-yl]-5-methyl-3-(2-methylpropyl)-1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC[C@H]1COC(C2=C(C=3C(=O)N(CC(C)C)C(=O)NC=3S2)C)=N1 JQJTULYLWIREKP-JTQLQIEISA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000029197 Amphetamine-Related disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 208000009132 Catalepsy Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- FSTUTPDEYUBTEL-UHFFFAOYSA-N N,3,5-trimethyl-2,4-dioxo-1H-thieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1C(=O)N(C)C(=O)C2=C1SC(C(=O)NC)=C2C FSTUTPDEYUBTEL-UHFFFAOYSA-N 0.000 claims 1
- RFVOIJHSHNFZIY-UHFFFAOYSA-N N,5-dimethyl-4-oxo-3-(2-oxopropyl)-1,2-dihydrothieno[2,3-d]pyrimidine-6-carboxamide Chemical compound CNC(=O)C1=C(C2=C(NCN(C2=O)CC(C)=O)S1)C RFVOIJHSHNFZIY-UHFFFAOYSA-N 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000026251 Opioid-Related disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 206010047853 Waxy flexibility Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- HSHDZEONKFFGNS-UHFFFAOYSA-N ethyl 3,5-dimethyl-2,4-dioxo-1h-thieno[2,3-d]pyrimidine-6-carboxylate Chemical compound N1C(=O)N(C)C(=O)C2=C1SC(C(=O)OCC)=C2C HSHDZEONKFFGNS-UHFFFAOYSA-N 0.000 claims 1
- LZYZNQYQLYGALK-UHFFFAOYSA-N ethyl 5-methyl-2,4-dioxo-3-prop-2-ynyl-1h-thieno[2,3-d]pyrimidine-6-carboxylate Chemical compound N1C(=O)N(CC#C)C(=O)C2=C1SC(C(=O)OCC)=C2C LZYZNQYQLYGALK-UHFFFAOYSA-N 0.000 claims 1
- 230000003492 excitotoxic effect Effects 0.000 claims 1
- 231100000063 excitotoxicity Toxicity 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000005040 opiate dependence Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 125000005156 substituted alkylene group Chemical group 0.000 claims 1
- 230000024883 vasodilation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77882106P | 2006-03-02 | 2006-03-02 | |
| US81574506P | 2006-06-21 | 2006-06-21 | |
| PCT/US2007/063143 WO2007103776A2 (en) | 2006-03-02 | 2007-03-02 | A2a adenosine receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009528389A JP2009528389A (ja) | 2009-08-06 |
| JP2009528389A5 true JP2009528389A5 (https=) | 2011-04-07 |
Family
ID=38475714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008557512A Pending JP2009528389A (ja) | 2006-03-02 | 2007-03-02 | Ａ２ａアデノシン受容体拮抗剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070208040A1 (https=) |
| EP (1) | EP1989210A2 (https=) |
| JP (1) | JP2009528389A (https=) |
| CA (1) | CA2644996A1 (https=) |
| WO (1) | WO2007103776A2 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906518B2 (en) * | 2006-06-27 | 2011-03-15 | Cbt Development Limited | Therapeutic compounds |
| WO2008070529A2 (en) * | 2006-12-01 | 2008-06-12 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
| GB0718434D0 (en) * | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
| GB0718432D0 (en) * | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
| TWI473614B (zh) | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
| US20100093723A1 (en) * | 2008-10-13 | 2010-04-15 | Barbay J Kent | HETEROCYCLYL AND CYCLOALKYL SUBSTITUTED THIENO[2,3 d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| US20100093722A1 (en) * | 2008-10-13 | 2010-04-15 | Barbay J Kent | HETEROARYL AND PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| US20100093721A1 (en) * | 2008-10-13 | 2010-04-15 | Barbay J Kent | PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| EP2501706B1 (en) | 2009-11-18 | 2014-08-06 | Council of Scientific & Industrial Research | A novel 3-substituted 7-imino-2-thioxo-3, 7-dihydro-2h-thiazolo [4,5-di pyrimidin-6-yl - and process for preparation thereof |
| RS57157B1 (sr) | 2011-11-11 | 2018-07-31 | Gilead Apollo Llc | Acc inhibitori i njihove primene |
| JP6417402B2 (ja) * | 2013-05-10 | 2018-11-07 | ギリアド アポロ， エルエルシー | Ａｃｃ阻害剤及びその使用 |
| JP6417401B2 (ja) * | 2013-05-10 | 2018-11-07 | ギリアド アポロ， エルエルシー | Ａｃｃ阻害剤及びその使用 |
| AU2014262547A1 (en) | 2013-05-10 | 2015-11-26 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
| EP2994139B1 (en) | 2013-05-10 | 2019-04-10 | Gilead Apollo, LLC | Acc inhibitors and uses thereof |
| KR20160065957A (ko) | 2013-10-07 | 2016-06-09 | 바이엘 파마 악티엔게젤샤프트 | 시클릭 티에노우라실-카르복스아미드 및 그의 용도 |
| EP3134729A1 (en) | 2014-04-22 | 2017-03-01 | Q-State Biosciences, Inc. | Analysis of compounds for pain and sensory disorders |
| JP6573968B2 (ja) * | 2014-08-11 | 2019-09-11 | ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | ＴＲＰＣ５調節因子としての、精神神経障害の処置のためのチエノおよびフロ［２，３−ｄ］ピリミジン−２，４［１Ｈ，３Ｈ］−ジオン誘導体 |
| US12006328B2 (en) | 2014-11-18 | 2024-06-11 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto |
| UY36586A (es) * | 2015-03-26 | 2016-10-31 | Bayer Pharma AG | Heterociclilmetiltienouracilos y uso de los mismos |
| AR106472A1 (es) | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | Inhibidores de acc y usos de los mismos |
| AU2016361412A1 (en) | 2015-11-25 | 2018-05-24 | Gilead Apollo, Llc | Pyrazole ACC inhibitors and uses thereof |
| EA201890949A1 (ru) | 2015-11-25 | 2018-12-28 | Джилид Аполло, Ллс | СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ |
| PL3380479T3 (pl) | 2015-11-25 | 2023-05-08 | Gilead Apollo, Llc | Triazolowe inhibitory acc i ich zastosowania |
| BR112018009212B1 (pt) | 2015-11-25 | 2022-06-14 | Gilead Apollo, Llc | Método para controlar patógenos fúngicos agrícolas |
| SG11201807077RA (en) | 2016-03-02 | 2018-09-27 | Gilead Apollo Llc | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
| WO2018041771A1 (de) | 2016-09-02 | 2018-03-08 | Bayer Pharma Aktiengesellschaft | (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung |
| CA3037642A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Aktiengesellschaft | N 3 -cyclically substituted thienouraciles and use thereof |
| EP3571205B1 (en) | 2017-01-22 | 2023-08-30 | Sunshine Lake Pharma Co., Ltd. | Thienopyrimidine derivative and use thereof in medicine |
| SI4122464T1 (sl) | 2017-03-28 | 2024-07-31 | Gilead Sciences, Inc. | Terapevtske kombinacije za zdravljenje bolezni jeter |
| JP7273732B2 (ja) * | 2017-05-31 | 2023-05-15 | ノバルティス アーゲー | ５－ブロモ－２，６－ジ（１ｈ－ピラゾール－１－イル）ピリミジン－４－アミン及び新たな塩の結晶形 |
| TW201910338A (zh) * | 2017-07-26 | 2019-03-16 | 大陸商南京聖和藥業股份有限公司 | 作為acc抑制劑的化合物及其應用 |
| WO2020139803A1 (en) * | 2018-12-24 | 2020-07-02 | Dcb-Usa Llc | Benzothiadiazine derivatives and compositions comprising the same for treating disorders mediated by adenosine |
| EP3995498A4 (en) | 2019-07-02 | 2023-03-01 | Sunshine Lake Pharma Co., Ltd. | THIENOPYRIMIDI DERIVATIVES WITH STEREO CONFIGURATION AND THEIR USE IN MEDICINE |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| EP0335979A4 (en) * | 1987-09-16 | 1992-02-26 | Taiho Pharmaceutical Company, Limited | Thienopyrimidine derivatives |
| DK522187D0 (da) * | 1987-10-06 | 1987-10-06 | Ferrosan As | Imidozothienopyrimidiner, deres fremstilling og anvendelse |
| US6878715B1 (en) * | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
| US5869486A (en) * | 1995-02-24 | 1999-02-09 | Ono Pharmaceutical Co., Ltd. | Fused pyrimidines and pyriazines as pharmaceutical compounds |
| SE9702001D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
| DE69912618T2 (de) * | 1998-08-28 | 2004-10-28 | Astrazeneca Ab | NEUE THIENO[2,3-d]PYRIMIDINDIONE, VERFAHREN FÜR IHRE HERSTELLUNG UND IHRE VERWENDUNG IN DER THERAPIE |
| HUP0203371A3 (en) * | 1999-11-12 | 2005-02-28 | Biogen Idec Ma Inc Cambridge | Adenosine receptor antagonists and methods of making and using the same |
| WO2001062233A2 (en) * | 2000-02-25 | 2001-08-30 | F. Hoffmann La Roche Ag | Adenosine receptor modulators |
| GB0100620D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical cokpounds V |
| EP1370562A1 (en) * | 2001-02-14 | 2003-12-17 | Warner-Lambert Company LLC | Thieno[2,3-d]pyrimidindione derivatives as matrix metalloproteinase inhibitors |
| EP1465634B1 (en) * | 2001-12-12 | 2014-10-22 | The Government of the United States of America, as represented by the Secretary Department of Health and Human Services | Methods for using adenosine receptor inhibitors to enhance immune response and inflammation |
| ES2208063B1 (es) * | 2002-04-01 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida. |
| WO2004006913A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| BR0312943A (pt) * | 2002-07-17 | 2005-07-12 | Warner Lambert Co | Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib |
| CA2524778C (en) * | 2003-05-06 | 2013-01-29 | Cv Therapeutics, Inc. | Xanthine derivatives as a2b adenosine receptor antagonists |
| MXPA05012369A (es) * | 2003-05-21 | 2006-02-02 | Hoffmann La Roche | Derivados de benzotiazol y uso de los mismos en el tratamiento de enfermedades relacionadas con el receptor a2a de adenosina. |
| US7449473B2 (en) * | 2003-10-31 | 2008-11-11 | Cv Therapeutics, Inc. | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists |
| US7523193B2 (en) * | 2004-05-18 | 2009-04-21 | International Business Machines Corporation | Method and apparatus for DNS pre-fetching for multiple clients |
| WO2008070529A2 (en) * | 2006-12-01 | 2008-06-12 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
-
2007
- 2007-03-02 CA CA002644996A patent/CA2644996A1/en not_active Abandoned
- 2007-03-02 WO PCT/US2007/063143 patent/WO2007103776A2/en not_active Ceased
- 2007-03-02 US US11/681,378 patent/US20070208040A1/en not_active Abandoned
- 2007-03-02 JP JP2008557512A patent/JP2009528389A/ja active Pending
- 2007-03-02 EP EP07757782A patent/EP1989210A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009528389A5 (https=) | ||
| JP5412429B2 (ja) | 抗細菌性アミド及びスルホンアミド置換複素環式尿素化合物 | |
| AU2014291142B2 (en) | Cyanotriazole compounds | |
| JP6094975B2 (ja) | Ａｌｋ５及び／又はａｌｋ４の抑制剤としての２−ピリジル置換イミダゾール類 | |
| ES2441178T3 (es) | Derivados de 2-oxo-1-pirrolidina, procedimientos para prepararlos y el uso terapéutico de los mismos sobre el sistema nervioso central | |
| KR101626627B1 (ko) | 아미도-티오펜 화합물 및 이의 용도 | |
| TWI338691B (en) | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | |
| JP5739662B2 (ja) | ５，６−ジヒドロ−１ｈ−ピリジン−２−オン化合物 | |
| AU2010332955B2 (en) | 3,4,4a,10b-tetrahydro-1H-thiopyrano-[4, 3-c] isoquinoline derivatives | |
| JP5969505B2 (ja) | 自己免疫性炎症の治療のためのＩＬ１７及びＩＦＮ−γ阻害 | |
| JP2009528389A (ja) | Ａ２ａアデノシン受容体拮抗剤 | |
| WO2012129258A1 (en) | Amidopyrazole inhibitors of interleukin receptor-associated kinases | |
| WO2013182972A1 (en) | Benzimidazole-proline derivatives | |
| CA2616428A1 (en) | Pyrazine derivatives useful as adenosine receptor antagonists | |
| AU2008276521A1 (en) | Heterocyclic modulators of PKB | |
| CN109153649A (zh) | 烟碱乙酰胆碱受体的变构调节剂 | |
| JP2014532626A5 (https=) | ||
| JP2010502659A (ja) | 新規置換ビピリジン誘導体およびアデノシン受容体リガンドとしてのそれらの使用 | |
| TW200529830A (en) | A thiazole derivative | |
| JP2013536193A (ja) | ヘテロアリール類およびその使用 | |
| US20110224208A1 (en) | Novel inhibitors of flavivirus replication | |
| WO2012085857A1 (en) | 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides | |
| CN111886233A (zh) | 新型三唑酮衍生物或其盐以及包含其的药物组合物 | |
| KR102390234B1 (ko) | 트리시클릭 피페리딘 화합물 | |
| US20100280023A1 (en) | Thiazole derivatives |